Several domains from VAR2CSA can induce Plasmodium falciparum adhesion-blocking antibodies.
BACKGROUND
Malaria caused by Plasmodium falciparum can result in several different syndromes with severe clinical consequences for the about 200 million individuals infected each year. During pregnancy, women living in endemic areas become susceptible to malaria due to lack of antibodies against a unique P. falciparum membrane protein, named VAR2CSA. This antigen is not expressed in childhood infections, since it binds chondroitin sulphate A (CSA) expressed on the intervillous space in the placenta. A vaccine appears possible because women acquire protective antibodies hindering sequestration in the placenta as a function of parity. A challenge for vaccine development is to design small constructs of this large antigen, which can induce broadly protective antibodies. It has previously been shown that one domain of VAR2CSA, DBL4-FCR3, induces parasite adhesion-blocking antibodies. In this study, it is demonstrated that other domains of VAR2CSA also can induce antibodies with inhibitory activity.


METHODS
All VAR2CSA domains from the 3D7 and HB3 parasites were produced in Baculovirus-transfected insect cells. Groups of three rats per protein were immunized and anti-sera were tested for surface reactivity against infected erythrocytes expressing FCR3 VAR2CSA and for the ability to inhibit FCR3CSA parasite adhesion to CSA. The fine specificity of the immune sera was analysed by VAR2CSA peptide arrays.


RESULTS
Inhibitory antibodies were induced by immunization with DBL3-HB3 T1 and DBL1-3D7. However, unlike the previously characterised DBL4-FCR3 response the inhibitory response against DBL1-3D7 and DBL3-HB3 T1 was poorly reproduced in the second rounds of immunizations.


CONCLUSIONS
It is possible to induce parasite adhesion-blocking antibodies when immunizing with a number of different VAR2CSA domains. This indicates that the CSA binding site in VAR2CSA is comprised of epitopes from different domains.
Salanti
Ali
A
Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen and Department of Infectious Diseases, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark. salanti@sund.ku.dk
Resende
Mafalda
M
Ditlev
Sisse B
SB
Pinto
Vera V
VV
Dahlbäck
Madeleine
M
Andersen
Gorm
G
Manczak
Tom
T
Theander
Thor G
TG
Nielsen
Morten A
MA
D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology*; D000913:Antibodies, Protozoan / Q000276:immunology*; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology*; D016367:Baculoviridae / Q000235:genetics; D002448:Cell Adhesion / Q000276:immunology*; D005260:Female; D005822:Genetic Vectors; D006801:Humans; D007313:Insecta; D017780:Malaria Vaccines / Q000235:genetics / Q000276:immunology*; D011247:Pregnancy; D017434:Protein Structure, Tertiary; D051381:Rats; D017208:Rats, Wistar; D022223:Vaccines, Subunit / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology
D057134:Antibodies, Neutralizing; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D017780:Malaria Vaccines; C512601:VAR2CSA protein, Plasmodium falciparum; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic